Brief Report: Acamprosate in Fragile X Syndrome

被引：0
作者：
Craig A. Erickson
Jennifer E. Mullett
Christopher J. McDougle
机构：
[1] Indiana University School of Medicine,Department of Psychiatry
[2] James Whitcomb Riley Hospital for Children,Christian Sarkine Autism Treatment Center
来源：
Journal of Autism and Developmental Disorders | 2010年 / 40卷
关键词：
Acamprosate; Fragile X syndrome; mGluR5; Language; Irritability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
引用
收藏
页码：1412 / 1416
页数：4
相关论文
共 122 条
[1]  
al Qatari M(2001)Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain Alcoholism, Clinical and Experimental Research 25 1276-1283
[2]  
Khan S(2004)The mGluR theory of fragile X mental retardation Trends in Neurosciences 27 370-377
[3]  
Harris B(2009)A pilot open label, single dose trial of fenobam in adults with fragile X syndrome Journal of Medical Genetics 46 266-271
[4]  
Littleton J(2008)Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome Journal of Developmental and Behavioral Pediatrics 29 293-302
[5]  
Bear MF(2008)Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions International Journal of Neuropsychopharmacology 11 775-793
[6]  
Huber KM(2005)Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model Journal of Neuroscience 25 8048-8055
[7]  
Warren ST(2009)Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: An experimental therapeutic approach for the Fmr1 deficiency Neuropsychopharmacology 34 1011-1026
[8]  
Berry-Kravis E(2008)Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice Neurobiology of Diseases 31 127-132
[9]  
Hessl D(2005)Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action CNS Drugs 19 517-537
[10]  
Coffey S(1993)The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation Nature Genetics 4 335-340
12345678910